GlassScriptPhysician profile
Charles A Duncan
NPI 1215932462
$10,310.47
in general payments reported to CMS, 2019-2025
41 companies · $2,222 in 2025
The $2,222 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $289 · 2021: $823 · 2022: $1,927 · 2023: $2,072 · 2024: $1,972 · 2025: $2,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,266.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,596.85 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,375.53 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,080.73 | 2019-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $617.05 | 2019-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $494.75 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $445.02 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $428.01 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Medtronic USA, INC. | $371.03 | 2019 | |
| Insmed, INC. | $362.81 | 2022-2025 | Arikayce, Brinsupri |
| Ethicon INC. | $356.24 | 2022-2023 | Monarch Platform |
| Janssen Pharmaceuticals, INC | $342.57 | 2021-2022 | |
| Electromed, INC. | $338.90 | 2022-2025 | Smartvest |
| Baxter Healthcare | $304.09 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Genzyme Corporation | $299.83 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $235.82 | 2021-2025 | Glassia |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $223.72 | 2022-2025 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $185.07 | 2019-2025 | |
| Philips North America LLC | $180.47 | 2020-2024 | (Ak6) Vest Therapy |
| Abbvie INC. | $139.37 | 2022-2025 | Avycaz |
| Verona Pharma, INC. | $122.22 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $115.21 | 2024-2025 | Acthar |
| Viatris Specialty LLC | $90.21 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $79.15 | 2025 | Winrevair |
| Fisher & Paykel Healthcare INC | $70.15 | 2023-2024 | Fisher & Paykel Healthcare |
| Gilead Sciences, INC. | $50.70 | 2023-2024 | Veklury |
| Pulmonx Corporation | $50.25 | 2023-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Ani Pharmaceuticals, INC. | $44.81 | 2024-2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $40.41 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.54 | 2023-2025 | |
| Shionogi INC | $30.39 | 2022 | |
| Advanced Respiratory, INC | $29.69 | 2021 | |
| Amgen INC. | $29.66 | 2021-2024 | Tezspire |
| Genentech USA, INC. | $24.11 | 2019-2020 | |
| Vifor Pharma, INC. | $18.88 | 2024 | Veltassa |
| Teva Pharmaceuticals USA, INC. | $17.90 | 2022 | |
| Tactile Systems Technology INC | $16.73 | 2023 | Entre Plus, Flexitouch Plus |
| Paratek Pharmaceuticals, INC. | $16.67 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $15.62 | 2019 | |
| Inogen, INC. | $13.43 | 2020 | |
| Portola Pharmaceuticals, LLC | $13.38 | 2020 | |
| Shire North American Group INC | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.